Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [08/28/2025 07:23 PDT] ARDX Expected to Trade Up After Bullish Patterns Develop
• [08/22/2025 10:30 PDT] Ardelyx, Inc. (NASDAQ:ARDX), Up By 100% ($5.2) From $5.2 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [08/21/2025 07:25 PDT] ARDX Expected to Trade Down After Bearish Patterns Develop
• [08/14/2025 07:16 PDT] ARDX Expected to Trade Up After Bullish Patterns Develop
• [08/13/2025 10:30 PDT] Ardelyx, Inc. (NASDAQ:ARDX), Up By 100% ($5.13) From $5.13 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [08/07/2025 07:14 PDT] ARDX Expected to Trade Up After Bullish Patterns Develop
• [08/06/2025 07:30 PDT] ARDX Expected to Trade Up Short Term
• [08/05/2025 09:51 PDT] Ardelyx, Inc. (NASDAQ:ARDX), Up By 100% ($4.39) From $4.39 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [08/05/2025 07:19 PDT] ARDX Expected to Trade Up After Bullish Patterns Develop
• [08/01/2025 10:29 PDT] Ardelyx, Inc. (NASDAQ:ARDX), Down By 100% ($4.6) From $4.6 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions